Breast Cancer News
Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
Researchers are conducting a phase 2 study to compare trastuzumab-based treatment regimens in patients with advanced HER2+ breast cancer.
Researchers are conducting a phase 1 study to test capecitabine in combination with cemiplimab in patients with HR+ metastatic breast cancer.
Researchers are conducting a phase 2 study to determine if ctDNA can be used to guide treatment in patients with ER+, HER2- breast cancer at high risk of recurrence.
Researchers are conducting a phase 2 study to test the safety and efficacy of durvalumab in combination with trastuzumab and pertuzumab for HER2-enriched breast cancer.
Screening for breast, cervical, and colorectal cancer decreased from prepandemic levels in early 2020, rebounded in late 2020, and decreased again in 2021.
Axillary radiotherapy can replace axillary lymph node dissection in patients with sentinel node-positive early breast cancer, according to researchers.
Breast cancer survivors who were active or moderately active had significantly reduced risk of death.
Results of a phase 3 trial suggest 18F-NaF PET-CT is more effective than 99mTc-MDP SPECT for detecting bone metastasis in patients with breast or prostate cancer.
Dose-dense adjuvant chemotherapy improves disease-free survival in high-risk early breast cancer, according to updated results from the GIM2 trial.
Acupuncture can reduce aromatase inhibitor-related joint pain in women with early breast cancer, a study suggests.
Adding abemaciclib to adjuvant endocrine therapy improves outcomes in patients with high-risk early breast cancer, data suggest.
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
Margetuximab does not provide an overall survival benefit over trastuzumab in patients with previously treated, HER2-positive breast cancer, a phase 3 trial suggests.
Breast and prostate cancer mortality rates were higher in AIAN individuals than in White individuals, despite lower incidence rates.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Treating oligoprogression with SBRT improved progression-free survival in patients with lung cancer but not in those with breast cancer.
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Omission of surgery may be possible for women with early-stage breast cancer who are exceptional responders to neoadjuvant systemic therapy.